• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine: Real world experience in India.

作者信息

Shah Bela, De Abhishek, Sarda Aarti, Kochhar Atul M, Dhoot Dhiraj, Deshmukh Gaurav, Barkate Hanmant

机构信息

Department of Dermatology, Venereology, and Leprosy, B.J. Medical College, Civil Hospital, Ahmedabad.

Department of Dermatology, Calcutta National Medical College, Calcutta, India.

出版信息

Dermatol Ther. 2021 Jan;34(1):e14557. doi: 10.1111/dth.14557. Epub 2020 Nov 27.

DOI:10.1111/dth.14557
PMID:33210404
Abstract
摘要

相似文献

1
Effect of bilastine on chronic spontaneous urticaria refractory to levocetrizine: Real world experience in India.比拉斯汀对左旋西替利嗪难治性慢性自发性荨麻疹的疗效：印度的真实世界经验。
Dermatol Ther. 2021 Jan;34(1):e14557. doi: 10.1111/dth.14557. Epub 2020 Nov 27.
2
Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.20毫克比拉斯汀与5毫克左西替利嗪治疗慢性自发性荨麻疹的有效性、安全性及耐受性：一项双盲、平行组、随机对照试验
Dermatol Ther. 2020 Nov;33(6):e13946. doi: 10.1111/dth.13946. Epub 2020 Jul 27.
3
Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.比拉斯汀在日本慢性自发性荨麻疹患者中的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行组II/III期研究。
Allergol Int. 2017 Apr;66(2):317-325. doi: 10.1016/j.alit.2016.08.004. Epub 2016 Sep 2.
4
Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.比拉斯汀与左西替利嗪治疗慢性特发性荨麻疹的疗效与安全性：一项多中心、双盲、双模拟、III期、非劣效性随机临床试验。
Chin Med J (Engl). 2024 Jun 20;137(12):1480-1482. doi: 10.1097/CM9.0000000000003071. Epub 2024 Apr 1.
5
Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study.比拉斯汀增加剂量治疗中度至重度慢性自发性荨麻疹有效：一项真实世界研究
Allergy. 2018 Oct;73(10):2073-2075. doi: 10.1111/all.13494. Epub 2018 Jul 17.
6
Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.比较比利司特 20 毫克与左西替利嗪 5 毫克治疗慢性特发性荨麻疹的疗效和安全性：一项多中心、双盲、随机、安慰剂对照研究。
Allergy. 2010 Apr;65(4):516-28. doi: 10.1111/j.1398-9995.2009.02217.x. Epub 2009 Oct 23.
7
Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.将组胺 H1 受体拮抗剂比拉斯汀转换为治疗慢性自发性荨麻疹患者的疗效（H1-SWITCH）：一项随机对照试验的研究方案。
Trials. 2020 Jan 6;21(1):23. doi: 10.1186/s13063-019-3878-2.
8
One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.比拉斯汀治疗日本慢性自发性荨麻疹或与皮肤疾病相关瘙痒症患者的一年安全性和疗效研究。
J Dermatol. 2017 Apr;44(4):375-385. doi: 10.1111/1346-8138.13644. Epub 2016 Nov 14.
9
Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.比拉斯汀在减轻慢性自发性荨麻疹及其他皮肤病患者瘙痒方面的疗效和安全性：一项探索性研究。
J Dermatolog Treat. 2020 May;31(3):270-278. doi: 10.1080/09546634.2019.1590522. Epub 2019 Apr 2.
10
Safety profile of bilastine: 2nd generation H1-antihistamines.比拉斯汀的安全性特征：第二代 H1 抗组胺药。
Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1999-2005.

引用本文的文献

1
Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria.比拉斯汀治疗自身免疫性慢性自发性荨麻疹患者后的临床及生活质量改善情况
PLoS One. 2025 Aug 25;20(8):e0326445. doi: 10.1371/journal.pone.0326445. eCollection 2025.
2
Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine.重新构想的比拉斯汀：用新型抗组胺药全面探索瘙痒症的治疗
Cureus. 2024 Oct 10;16(10):e71232. doi: 10.7759/cureus.71232. eCollection 2024 Oct.
3
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study.
在难治性慢性自发性荨麻疹（H1-SWITCH）患者中转换为 H1 抗组胺药比拉斯汀的疗效和安全性：一项多中心、开放标签、随机、平行组比较研究。
Front Immunol. 2024 Sep 16;15:1441478. doi: 10.3389/fimmu.2024.1441478. eCollection 2024.
4
An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria.一项开放标签、研究者发起的单中心试点研究，以确定托法替布治疗难治性慢性自发性荨麻疹的安全性和有效性。
Indian J Dermatol. 2024 Jul-Aug;69(4):312-316. doi: 10.4103/ijd.ijd_1085_23. Epub 2024 Aug 19.
5
Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.比拉斯汀治疗难治性慢性自发性荨麻疹：一项开放标签前瞻性研究中的疾病控制和细胞因子调节
Indian J Dermatol. 2024 Mar-Apr;69(2):132-136. doi: 10.4103/ijd.ijd_722_23. Epub 2024 Apr 29.
6
Advances in clinical application of H antihistamines in the treatment of skin diseases.H 抗组胺药在皮肤病治疗中的临床应用进展。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Feb 28;49(2):182-189. doi: 10.11817/j.issn.1672-7347.2024.230452.
7
Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.在印度，针对对其他抗组胺药双倍剂量治疗无效的慢性自发性荨麻疹（CSU）患者，转换为每日40毫克比拉斯汀治疗的真实世界经验。
Indian J Dermatol. 2023 Nov-Dec;68(6):674-677. doi: 10.4103/ijd.ijd_89_23. Epub 2024 Jan 9.
8
Diagnosis and Management of Urticaria in Indian Settings: Skin Allergy Research Society's Guideline-2022.印度环境下荨麻疹的诊断与管理：皮肤过敏研究学会2022年指南
Indian J Dermatol. 2022 Nov-Dec;67(6):732-743. doi: 10.4103/ijd.ijd_307_22.
9
A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.一项比较性、三臂、随机临床试验，旨在评估在慢性自发性荨麻疹患者中，标准剂量的比拉斯汀与非索非那定、左西替利嗪的有效性和耐受性，以及高剂量（增量给药）的比拉斯汀与非索非那定、左西替利嗪及羟嗪（联合用药）的有效性和耐受性。
Clin Cosmet Investig Dermatol. 2022 Feb 18;15:261-270. doi: 10.2147/CCID.S350122. eCollection 2022.